Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial

Rationale and design of the phase 3a development programme ( ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes

(2022) Athena Philis‐Tsimikas et al.   DIABETES OBESITY & METABOLISM

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023

(2022) Nuha A. ElSayed et al.   DIABETES CARE

Continuous glucose monitoring and metrics for clinical trials: an international consensus statement

(2022) Tadej Battelino et al.   Lancet Diabetes & Endocrinology

Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial

(2021) Harpreet S. Bajaj et al.   DIABETES CARE

A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100

(2021) Ildiko Lingvay et al.   DIABETES CARE

Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans

(2021) Thomas B. Kjeldsen et al.   JOURNAL OF MEDICINAL CHEMISTRY

Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing

(2021) Erica Nishimura et al.   BMJ Open Diabetes Research & Care

Basal weekly insulins: the way of the future!

(2021) Julio Rosenstock et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study)

(2021) William H. Polonsky et al.   Diabetes Therapy

Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment

(2020) Julio Rosenstock et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range

(2019) Tadej Battelino et al.   DIABETES CARE

Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes

(2019) Simon R. Heller et al.   DIABETES CARE

Addressing Clinical Inertia in Type 2 Diabetes Mellitus: A Review

(2018) Jennifer Okemah et al.   ADVANCES IN THERAPY

Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States

(2018) Reema Mody et al.   DIABETES OBESITY & METABOLISM

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes

(2017) Carol Wysham et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes: Table 1

(2016)   DIABETES CARE

Attitudes towards insulin initiation in type 2 diabetes patients among healthcare providers: A survey research

(2016) Javier Escalada et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long)

(2012) B. Zinman et al.   DIABETES CARE

Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study

(2012) M. Peyrot et al.   DIABETIC MEDICINE

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

(2012) Alan J Garber et al.   LANCET

A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence

(2012) Carla Dias-Barbosa et al.   Patient Preference and Adherence

Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes

(2011) Stuart A. Ross et al.   CURRENT MEDICAL RESEARCH AND OPINION

Barriers to Insulin Initiation: The Translating Research Into Action for Diabetes Insulin Starts Project

(2010) A. J. Karter et al.   DIABETES CARE

Patient perspectives on once-weekly medications for diabetes

(2010) W. H. Polonsky et al.   DIABETES OBESITY & METABOLISM

Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes

(2010) Ebenezer A. Nyenwe et al.   METABOLISM-CLINICAL AND EXPERIMENTAL